FY2024 EPS Estimates for Bruker Raised by Leerink Partnrs

Bruker Co. (NASDAQ:BRKR) – Leerink Partnrs boosted their FY2024 EPS estimates for shares of Bruker in a note issued to investors on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now expects that the medical research company will post earnings of $2.39 per share for the year, up from their prior forecast of $2.38. The consensus estimate for Bruker’s current full-year earnings is $2.39 per share. Leerink Partnrs also issued estimates for Bruker’s Q4 2024 earnings at $0.74 EPS, Q4 2025 earnings at $0.91 EPS, FY2025 earnings at $2.74 EPS, FY2026 earnings at $3.16 EPS and FY2027 earnings at $3.65 EPS.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.60 EPS for the quarter, missing analysts’ consensus estimates of $0.61 by ($0.01). Bruker had a net margin of 9.41% and a return on equity of 21.52%. The firm had revenue of $864.40 million for the quarter, compared to analysts’ expectations of $866.46 million. During the same quarter in the previous year, the company earned $0.74 EPS. The company’s quarterly revenue was up 16.4% compared to the same quarter last year.

BRKR has been the topic of several other research reports. Wolfe Research cut shares of Bruker from an “outperform” rating to a “peer perform” rating in a research note on Monday, September 30th. Citigroup dropped their target price on shares of Bruker from $80.00 to $75.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. UBS Group assumed coverage on shares of Bruker in a research note on Tuesday, December 10th. They set a “neutral” rating and a $66.00 target price for the company. Guggenheim reissued a “buy” rating on shares of Bruker in a report on Friday, January 17th. Finally, Wells Fargo & Company cut their price objective on Bruker from $78.00 to $75.00 and set an “overweight” rating for the company in a report on Wednesday, November 6th. Six investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $74.45.

Bruker Stock Up 0.1 %

Bruker stock opened at $60.12 on Wednesday. The firm has a market cap of $9.11 billion, a price-to-earnings ratio of 28.90, a PEG ratio of 3.32 and a beta of 1.17. The company has a current ratio of 1.66, a quick ratio of 0.73 and a debt-to-equity ratio of 1.24. Bruker has a 12 month low of $48.07 and a 12 month high of $94.86. The stock has a fifty day simple moving average of $57.96 and a two-hundred day simple moving average of $61.61.

Bruker Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, December 16th. Stockholders of record on Monday, December 2nd were issued a dividend of $0.05 per share. The ex-dividend date of this dividend was Monday, December 2nd. This represents a $0.20 annualized dividend and a dividend yield of 0.33%. Bruker’s dividend payout ratio is presently 9.62%.

Insider Activity

In other news, CEO Frank H. Laukien bought 100,000 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The shares were purchased at an average price of $50.14 per share, with a total value of $5,014,000.00. Following the purchase, the chief executive officer now owns 38,439,563 shares in the company, valued at approximately $1,927,359,688.82. The trade was a 0.26 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 28.30% of the company’s stock.

Institutional Trading of Bruker

Hedge funds have recently made changes to their positions in the business. FMR LLC increased its stake in Bruker by 21.4% during the 3rd quarter. FMR LLC now owns 14,306,122 shares of the medical research company’s stock worth $987,981,000 after buying an additional 2,521,904 shares during the period. State Street Corp increased its position in shares of Bruker by 9.6% during the third quarter. State Street Corp now owns 3,627,300 shares of the medical research company’s stock worth $250,501,000 after acquiring an additional 318,808 shares during the period. RTW Investments LP raised its stake in shares of Bruker by 1.1% in the third quarter. RTW Investments LP now owns 3,481,119 shares of the medical research company’s stock valued at $240,406,000 after acquiring an additional 37,024 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Bruker by 10.8% in the third quarter. Geode Capital Management LLC now owns 1,993,468 shares of the medical research company’s stock valued at $137,702,000 after purchasing an additional 193,580 shares during the period. Finally, Marshall Wace LLP grew its stake in Bruker by 127.8% during the 2nd quarter. Marshall Wace LLP now owns 1,389,537 shares of the medical research company’s stock worth $88,666,000 after purchasing an additional 779,549 shares in the last quarter. Institutional investors and hedge funds own 79.52% of the company’s stock.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.